Diagnosis and staging of cardiac masses: additional value of CMR with <sup>18</sup>F-FDG-PET compared to CMR with CECT.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35247063.
- Also identified by DOI 10.1007/s00259-022-05709-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Characterization of malignant cardiac masses is usually performed with cardiac magnetic resonance (CMR) and staging with whole-body contrast-enhanced computed tomography (CECT). In this study, our objective was to evaluate the role of <sup>18</sup>Fluor-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG-PET) with CMR for both characterization and staging of cardiac masses. Patients with cardiac masses who underwent CMR, CECT, and <sup>18</sup>F-FDG-PET were retrospectively identified. For the characterization of cardiac masses, we calculated the respective performances of CMR alone, <sup>18</sup>F-FDG-PET alone, and the combination of <sup>18</sup>F-FDG-PET and CMR. For staging, we compared head-to-head the respective performances of <sup>18</sup>F-FDG-PET and CECT. Histology served as gold standard for malignancy, and response to anticoagulation for thrombus. In a total of 28 patients (median age 60.5 years, 60.7% women), CMR accurately distinguished malignant from benign masses with sensitivity (Se) of 86.7%, specificity (Sp) of 100%, positive predictive value (PPV) of 100%, negative predictive value (NPV) of 86.7%, and accuracy of 92.9%. <sup>18</sup>F-FDG-PET demonstrated 93.3% Se, 84.6% Sp, 87.5% PPV, 91.7% NPV, and 89.3% accuracy. Combining CMR with <sup>18</sup>F-FDG-PET allowed to benefit from the high sensitivity of <sup>18</sup>F-FDG-PET (92.9%) and the excellent specificity of CMR (100%) for malignant diseases. For staging, <sup>18</sup>F-FDG-PET outperformed CECT on per-patient (66.7% vs 55.6% correct diagnosis, respectively), per-organ (10 vs 7 organs, respectively), and per-lesion basis (> 29 vs > 25 lesions, respectively). Combining <sup>18</sup>F-FDG-PET with CMR improved the characterization of cardiac masses compared to each modality alone. Additionally, the diagnostic performance of <sup>18</sup>F-FDG-PET was better than CECT for staging. This study suggests that the combination of CMR and <sup>18</sup>F-FDG-PET is the most effective for the characterization of cardiac masses and the staging of these lesions.
Medical subject headings
- Fluorodeoxyglucose F18
- Radiopharmaceuticals